Results for

""Phosphoinositide-3 Kinase Inhibitors""[mesh_terms]

Effective Medicinal Plant in Cancer Treatment, Part 2: Review Study.

Fatemeh Sadeghi, Majid Asadi-Samani, Karo Servatyari, Wesam Kooti, Masoud Behzadifar, Hadi Zare Marzouni, Bijan Nouri

Journal of evidence-based complementary & alternative medicine 2019;22(4):982-995

Model-informed approach to support pediatric dosing for the pan-PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors.

Peter N Morcos, Dirk Garmann, John Chung, Joel M Reid, Margaret E Macy, Barrett H Childs, Adam Lloyd, Jonathan Moss, Rolf Burghaus, Jan Schlender

Clinical and translational science 2023;16(7):1197-1209

Development of small-molecule inhibitors that target PI3Kβ.

Rong Sheng, Haodong Yang, Lvtao Cai, Dongyan Gu, Yanzhen Yu

Drug discovery today 2024;29(1):103854

A comprehensive review of small molecules targeting PI3K pathway: Exploring the structural development for the treatment of breast cancer.

Vivek Asati, Shankar Gupta, Anushka Sharma, Rahul Dubey, G D Gupta

Bioorganic chemistry 2024;143():107077

Effective Strategies for the Prevention and Mitigation of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia: Optimizing Patient Care.

Dylan M Zylla, Abigail M Johnston, Heather N Moore, Richard M Bergenstal, William J Gradishar, Hope S Rugo, Marcus D Goncalves, Erica L Mayer

Clinical breast cancer 2024;25(1):1-11

Phosphoinositide-3-kinase (PI3K) inhibitors: identification of new scaffolds using virtual screening.

Raphaël Frédérick, Claire Mawson, Jackie D Kendall, Claire Chaussade, Gordon W Rewcastle, Peter R Shepherd, William A Denny

Bioorganic & medicinal chemistry letters 2010;19(20):5842-7

Molecular mechanisms involved in DNA repair in human cancers: An overview of PI3k/Akt signaling and PIKKs crosstalk.

Forough Alemi, Aydin Raei Sadigh, Faezeh Malakoti, Yusuf Elhaei, Seyed Hamed Ghaffari, Masomeh Maleki, Zatollah Asemi, Bahman Yousefi, Niloufar Targhazeh, Maryam Majidinia

Journal of cellular physiology 2022;237(1):313-328

Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling.

Gabriella L Mariani, Thomas W Grunt

Current cancer drug targets 2013;13(2):188-204

Synergistic anti-proliferative and apoptotic effect of NVP-BEZ235 and curcumin on human SH-SY5Y neuroblastoma cells.

Fadime Çetin, Zeynep Busra Bolat, Hüseyin Abdik, Sifa Kosba

Medical oncology (Northwood, London, England) 2023;41(1):11

The PI3K inhibitor pictilisib and the multikinase inhibitors pazopanib and sorafenib have an impact on Rac1 level and migration of medulloblastoma in vitro.

Silvia Jordans, Dagmar Dilloo, Anja Troeger, Thomas Moritz, Torsten Pietsch, Rogerio B Craveiro, Leonie F Schoen

Journal of cellular and molecular medicine 2022;26(23):5832-5845

Trends in the early investigational drug development and areas for improvement.

Giuseppe Tonini

Expert opinion on investigational drugs 2016;24(7):845-50

A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.

Jennifer Vermette, Lillian L Siu, Kristen J Pierce, Nuzhat Pathan, Stephen Leong, Kenneth A Kern, Josep Tabernero, Brett Houk, Patrick Ezeh, Gianluca Del Conte, Carolyn D Britten, Irene Braña, Heloisa P Soares, Maria Alsina, Zev A Wainberg

Targeted oncology 2018;12(6):775-785

Clinical drug interaction profile of idelalisib in healthy subjects.

Feng Jin, Srini Ramanathan, Bernard Murray, Sibylle Wilbert, Candra Moyer, Huafeng Zhou, Michelle Robeson

Journal of clinical pharmacology 2016;55(8):909-19

Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy.

Devesh Tewari, Pooja Patni, Anusha Bishayee, Archana N Sah, Anupam Bishayee

Seminars in cancer biology 2022;80():1-17